• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肿瘤微环境刺激响应性纳米前药通过共递送 miRNA-21 调节剂克服吉西他滨化疗耐药性。

A tumor microenvironment-stimuli responsive nano-prodrug for overcoming gemcitabine chemoresistance by co-delivered miRNA-21 modulator.

机构信息

The Fourth Affiliated Hospital, International Institutes of Medicine, Zhejiang University School of Medicine, Yiwu 322000, People's Republic of China.

Department of Hepatobiliary and Pancreatic Surgery, First Affiliated Hospital, Zhejiang University School of Medicine, 79 Qingchun Road, Hangzhou 310003, People's Republic of China.

出版信息

Biomed Mater. 2023 Apr 14;18(3). doi: 10.1088/1748-605X/acc8ac.

DOI:10.1088/1748-605X/acc8ac
PMID:36990101
Abstract

Gemcitabine (Gem) has been recommended as a first-line clinical chemotherapeutics for pancreatic ductal adenocarcinoma (PDAC) treatment. Gem treatment could generate chemoresistance associated with abnormal expressions of multiple miRNAs. In the PDAC setting, miRNA-21 (miR-21) overexpression is an important contributing factor of inducing Gem chemoresistance. Inhibition of miR-21 can significantly increase Gem chemosensitivity, which requires an efficient delivery platform to conduct combinational Gem and miR-21 siRNA (miR-21i) therapy. Herein, we synthesized a tumor microenvironment (TME) stimuli-responsive poly(beta-amino ester)s (PBAE)-based polymer nano-prodrug (miR-21i@HA-Gem-SS-P12) that could co-deliver miR-21 siRNA and Gem. The disulfide linkages conjugating GEM onto PBAE can be triggered by elevated reduction stimulus in TME to release the cargo Gem. The hyaluronic acid (HA) fabrication further improved the drug accumulation at the tumor site. Benefiting from the multiple functional improvements and synergism between Gem and miR-21i, the miR-21i@HA-Gem-SS-P12 nano-prodrugs displayed superior tumor inhibition in PDACand. This study established an effective stimuli-responsive nano-prodrug strategy for cooperative treatment with small molecule agents and nucleotide modulators in PDAC.

摘要

吉西他滨(Gem)已被推荐为治疗胰腺导管腺癌(PDAC)的一线临床化疗药物。Gem 治疗可产生与多种 miRNA 异常表达相关的化疗耐药性。在 PDAC 环境中,miR-21(miR-21)过表达是诱导 Gem 化疗耐药的重要因素。抑制 miR-21 可显著提高 Gem 化疗敏感性,这需要一个有效的递送平台来进行联合 Gem 和 miR-21 siRNA(miR-21i)治疗。在这里,我们合成了一种肿瘤微环境(TME)刺激响应性聚(β-氨基酯)(PBAE)基聚合物纳米前药(miR-21i@HA-Gem-SS-P12),可共递送 miR-21 siRNA 和 Gem。连接 GEM 到 PBAE 上的二硫键可以被 TME 中升高的还原刺激触发,从而释放货物 Gem。透明质酸(HA)的制备进一步提高了药物在肿瘤部位的积累。得益于 Gem 和 miR-21i 之间的多种功能改进和协同作用,miR-21i@HA-Gem-SS-P12 纳米前药在 PDAC 中显示出优异的肿瘤抑制作用。本研究建立了一种有效的刺激响应性纳米前药策略,用于在 PDAC 中与小分子药物和核苷酸调节剂进行联合治疗。

相似文献

1
A tumor microenvironment-stimuli responsive nano-prodrug for overcoming gemcitabine chemoresistance by co-delivered miRNA-21 modulator.肿瘤微环境刺激响应性纳米前药通过共递送 miRNA-21 调节剂克服吉西他滨化疗耐药性。
Biomed Mater. 2023 Apr 14;18(3). doi: 10.1088/1748-605X/acc8ac.
2
Leptin-elicited miRNA-342-3p potentiates gemcitabine resistance in pancreatic ductal adenocarcinoma.瘦素诱导的 microRNA-342-3p 增强胰腺导管腺癌对吉西他滨的耐药性。
Biochem Biophys Res Commun. 2019 Feb 12;509(3):845-853. doi: 10.1016/j.bbrc.2019.01.030. Epub 2019 Jan 11.
3
Chemosensitization and inhibition of pancreatic cancer stem cell proliferation by overexpression of microRNA-205.通过过表达微小RNA-205实现胰腺癌干细胞的化学增敏作用及增殖抑制
Cancer Lett. 2017 Aug 28;402:1-8. doi: 10.1016/j.canlet.2017.05.007. Epub 2017 May 20.
4
Tumor Microenvironment Modulates Invadopodia Activity of Non-Selected and Acid-Selected Pancreatic Cancer Cells and Its Sensitivity to Gemcitabine and C18-Gemcitabine.肿瘤微环境调节非筛选和酸筛选的胰腺癌细胞侵袭伪足活性及其对吉西他滨和 C18-吉西他滨的敏感性。
Cells. 2024 Apr 23;13(9):730. doi: 10.3390/cells13090730.
5
MiRNA-3662 reverses the gemcitabine resistance in pancreatic cancer through regulating the tumor metabolism.miRNA-3662 通过调节肿瘤代谢逆转胰腺癌对吉西他滨的耐药性。
Cancer Chemother Pharmacol. 2021 Aug;88(2):343-357. doi: 10.1007/s00280-021-04289-z. Epub 2021 May 15.
6
UTMD-Promoted Co-Delivery of Gemcitabine and miR-21 Inhibitor by Dendrimer-Entrapped Gold Nanoparticles for Pancreatic Cancer Therapy.树状大分子包载金纳米载药系统促进吉西他滨和 miR-21 抑制剂联合递药用于胰腺癌治疗。
Theranostics. 2018 Feb 14;8(7):1923-1939. doi: 10.7150/thno.22834. eCollection 2018.
7
TIMP1 down-regulation enhances gemcitabine sensitivity and reverses chemoresistance in pancreatic cancer.TIMP1 下调增强吉西他滨敏感性并逆转胰腺癌的化疗耐药性。
Biochem Pharmacol. 2021 Jul;189:114085. doi: 10.1016/j.bcp.2020.114085. Epub 2020 Jun 6.
8
MicroRNA-155 Controls Exosome Synthesis and Promotes Gemcitabine Resistance in Pancreatic Ductal Adenocarcinoma.miRNA-155 控制外泌体的合成并促进胰腺导管腺癌对吉西他滨的耐药性。
Sci Rep. 2017 Feb 15;7:42339. doi: 10.1038/srep42339.
9
Gemcitabine-Lipid Conjugate and ONC201 Combination Therapy Effectively Treats Orthotopic Pancreatic Tumor-Bearing Mice.吉西他滨脂质偶联物与 ONC201 联合治疗有效治疗原位胰腺肿瘤荷瘤小鼠。
ACS Appl Mater Interfaces. 2024 Jun 12;16(23):29686-29698. doi: 10.1021/acsami.4c02626. Epub 2024 May 30.
10
Exosomes derived from cancer stem cells of gemcitabine-resistant pancreatic cancer cells enhance drug resistance by delivering miR-210.来源于吉西他滨耐药胰腺癌肿瘤干细胞的外泌体通过传递 miR-210 增强药物耐药性。
Cell Oncol (Dordr). 2020 Feb;43(1):123-136. doi: 10.1007/s13402-019-00476-6. Epub 2019 Nov 12.

引用本文的文献

1
Deciphering the role of NcRNAs in Pancreatic Cancer immune evasion and drug resistance: a new perspective for targeted therapy.解析非编码 RNA 在胰腺癌免疫逃逸和耐药中的作用:靶向治疗的新视角。
Front Immunol. 2024 Nov 1;15:1480572. doi: 10.3389/fimmu.2024.1480572. eCollection 2024.
2
Chemoresistance and the tumor microenvironment: the critical role of cell-cell communication.化疗耐药性与肿瘤微环境:细胞间通讯的关键作用。
Cell Commun Signal. 2024 Oct 10;22(1):486. doi: 10.1186/s12964-024-01857-7.